Transmedics Group Inc (TMDX) concluded trading on Thursday at a closing price of $66.50, with 3.19 million shares of worth about $212.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.53% during that period and on Thursday the price saw a gain of about 6.66%. Currently the company’s common shares owned by public are about 33.56M shares, out of which, 32.43M shares are available for trading.
Stock saw a price change of 4.07% in past 5 days and over the past one month there was a price change of -21.89%. Year-to-date (YTD), TMDX shares are showing a performance of 6.66% which decreased to -13.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.27 but also hit the highest price of $177.37 during that period. The average intraday trading volume for Transmedics Group Inc shares is 1.73 million. The stock is currently trading 2.76% above its 20-day simple moving average (SMA20), while that difference is down -16.83% for SMA50 and it goes to -44.65% lower than SMA200.
Transmedics Group Inc (NASDAQ: TMDX) currently have 33.56M outstanding shares and institutions hold larger chunk of about 109.84% of that.
The stock has a current market capitalization of $2.23B and its 3Y-monthly beta is at 2.12. PE ratio of stock for trailing 12 months is 71.24, while it has posted earnings per share of $0.93 in the same period. It has Quick Ratio of 7.33 while making debt-to-equity ratio of 2.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TMDX, volatility over the week remained 4.96% while standing at 5.96% over the month.
Stock’s fiscal year EPS is expected to rise by 226.39% while it is estimated to increase by 49.80% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on December 17, 2024 offering a Neutral rating for the stock and assigned a target price range of between $116 and $75 to it. On October 29, 2024, Oppenheimer Reiterated their recommendations, while on October 29, 2024, Needham Reiterated their ratings for the stock with a price target of $109. Stock get an Outperform rating from Robert W. Baird on September 24, 2024.
